Related Experiment Videos
Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory
P Richmond1, R Borrow, E Miller
1Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service (PHLS), London NW9 5EQ, United Kingdom. prichmon@phls.co.uk
Insights
This study shows a meningococcal C conjugate vaccine is safe and effective in infants. It generates a strong immune response and long-lasting protection against meningococcal C disease.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- Meningococcal C disease poses a significant risk to infants.
- Developing safe and effective vaccines is crucial for prevention.
- Assessing immunogenicity and safety in infant populations is essential.
Purpose of the Study:
- To evaluate the safety and immunogenicity of a meningococcal C oligosaccharide-CRM197 conjugate vaccine in infants.
- To compare two different dosages (2 mcg and 10 mcg) of the conjugate vaccine.
- To assess antibody persistence and response to a booster dose.
Main Methods:
- A study involving 114 infants vaccinated at 2, 3, and 4 months.
- Evaluation of two vaccine dosages: 2 mcg and 10 mcg.
- Measurement of antibody concentrations (GMC) and serum bactericidal antibody titers (GMT) before and after vaccination and boosting.
Main Results:
- The meningococcal conjugate vaccine demonstrated good tolerability with fewer local reactions compared to routine immunizations.
- Significant increases in serogroup C-specific immunoglobulin GMC and serum bactericidal antibody GMT were observed post-vaccination.
- The 10 mcg dose showed higher initial antibody responses, but the 2 mcg dose showed better response after polysaccharide boosting.
Conclusions:
- The meningococcal C conjugate vaccine is well-tolerated and immunogenic in infants.
- The vaccine effectively induces immunological memory, suggesting potential for long-term protection.
- Further research may be needed to optimize dosing strategies for sustained immunity.
Abstract:
The safety, immunogenicity, and immunologic priming of 2 dosages (2 microgram or 10 microgram) of a meningococcal C oligosaccharide-CRM197 conjugate vaccine was evaluated in 114 infants vaccinated at ages 2, 3, and 4 months. Antibody persistence and response to boosting with 10 microgram of meningococcal C polysaccharide were assessed. The meningococcal conjugate vaccine produced fewer local reactions than concurrent routine immunizations. Total serogroup C-specific immunoglobulin geometric mean concentration (GMC) increased from 0.3 microgram/mL before vaccination to 13.1 microgram/mL at age 5 months. Serum bactericidal antibody (SBA) geometric mean titers (GMTs) rose from <1:4 to 1:1057 at 5 months and fell by 14 months to 1:19. Following boosting, anti-C-specific immunoglobulin GMC rose to 15.9 microgram/mL and SBA GMT to 1:495. Antibody responses in the 10-microgram dose cohort were significantly higher at 5 months (P<.01) than in the 2-microgram dose cohort but were lower after polysaccharide boosting (P=.02). This meningococcal conjugate vaccine was well tolerated and immunogenic and induced immunologic memory in infants.